Meds to Treat Opioid Addiction Significantly Underused

This article originally appeared here.
Share this content:
Meds to Treat Opioid Addiction Significantly Underused
Meds to Treat Opioid Addiction Significantly Underused

FRIDAY, June 3, 2016 (HealthDay News) -- Too few patients are being prescribed any of the three available medications used to treat opioid use disorder in the 30 days after hospital discharge, according to a study published online June 1 in Psychiatric Services.

Sarah Naeger, Ph.D. M.P.H., of the U.S. Substance Abuse and Mental Health Services Administration, and colleagues examined data on 36,719 U.S. adults under the age of 65. All were hospitalized for opioid abuse, dependence, or overdose between 2010 and 2014.

In the month after leaving hospital, 16.7 percent of patients received a medication for opioid use disorder. The study also found that in that same month, more than a fifth of patients (22.4 percent) filled an opioid prescription. Antidepressant prescriptions were filled by 40 percent of patients, antipsychotic prescriptions were filled by 15.6 percent, and prescriptions for benzodiazepines were filled by 13.9 percent. And, 35 percent of patients did not fill any prescriptions at all in the month after hospital discharge. More than 7 percent of patients filled prescriptions for both a benzodiazepine and an opioid.

"These results can help inform development of targeted prevention, intervention, and treatment options for patients with opioid use disorders," according to a journal new release. "More effort is needed to ensure that patients hospitalized for opioid misuse are receiving recommended services, including approved medication and therapeutic services."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »